Core Viewpoint - Zealand Pharma A/S has announced the implementation of long-term incentive programs for 2025 aimed at aligning the interests of its Board of Directors, Corporate Management, and employees with those of shareholders, while also attracting and retaining top talent [1][2]. Long-term Incentive Program - The long-term incentive program includes the granting of restricted share units (RSUs) and performance share units (PSUs) to various stakeholders within the company [2][10]. - The program is designed to align with selected European and U.S. biotech peers and to drive long-term performance [2]. Board of Directors - A total of 29,169 RSUs have been awarded to Zealand Pharma's Board of Directors, with vesting occurring annually in equal tranches over three years [10][5]. - The maximum number of RSUs granted to any Board member is capped at 8,000, with specific monetary limits based on their roles [6]. - Board members are required to hold RSUs equivalent to 200% of their annual grant value within two years of their election [7]. Corporate Management - Zealand Pharma's Corporate Management has been awarded 96,788 PSUs and 96,788 RSUs, with an estimated fair market value of DKK 82.2 million [10][13]. - The PSUs vest based on predefined performance targets, with potential vesting ranging from 0% to 150% after three years [11][12]. - RSUs for Corporate Management will vest annually in equal tranches over three years [12]. Employee Grants - US employees have been awarded 18,502 RSUs, while employees in Denmark have received 128,519 RSUs, with respective estimated fair market values of DKK 7.9 million and DKK 54.6 million [10][17][20]. - RSUs for US employees and employees in Denmark will vest annually in equal tranches over three years, with conditions tied to continued employment [16][19]. Company Overview - Zealand Pharma A/S is a biotechnology company focused on the discovery and development of peptide-based medicines, with over 10 drug candidates in clinical development [22]. - The company has established partnerships with several major pharmaceutical companies and has a presence in both Denmark and the United States [22][23].

ST HELIER, Jersey, April 02, 2025 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc ("the Company" or "Caledonia") (NYSE AMERICAN, AIM and VFEX: CMCL) announces that, pursuant to the vesting of awards made under the 2015 Omnibus Equity Incentive Compensation Plan of the Company (the "Plan") and following the publication of financial results for the year ended December 31, 2024, a total of 80,230 common shares of no par value in the Company are being issued on or about April 4, 2025 to members of staff wi ...